NASDAQ:MRSN - Mersana Therapeutics Stock Price, Price Target & More

$15.86 -0.99 (-5.88 %)
(As of 04/25/2018 02:42 AM ET)
Previous Close$16.85
Today's Range$15.57 - $16.89
52-Week Range$12.45 - $21.01
Volume42,408 shs
Average Volume121,018 shs
Market Capitalization$380.84 million
P/E Ratio-4.93
Dividend YieldN/A
BetaN/A

About Mersana Therapeutics (NASDAQ:MRSN)

Mersana Therapeutics logoMersana Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability. Its lead product candidates include XMT-1522, an ADC targeting HER2-expressing tumors, which is in Phase I clinical trial for treating patients with breast cancer, non-small-cell-lung-cancer (NSCLC), and gastric cancer; and XMT-1536, an ADC targeting NaPi2b that is in Phase I clinical trial for the treatment of patients with ovarian cancer, NSCLC, and other cancers. Mersana Therapeutics, Inc. has strategic alliances with Takeda Pharmaceutical Company Limited; Merck KGaA; and Asana BioSciences, LLC. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2002 and is based in Cambridge, Massachusetts.

Receive MRSN News and Ratings via Email

Sign-up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:MRSN
CUSIPN/A
Phone617-498-0020

Debt

Debt-to-Equity RatioN/A
Current Ratio3.69%
Quick Ratio3.69%

Price-To-Earnings

Trailing P/E Ratio-4.93
Forward P/E Ratio-6.27
P/E GrowthN/A

Sales & Book Value

Annual Sales$17.55 million
Price / Sales20.65
Cash FlowN/A
Price / CashN/A
Book Value$3.08 per share
Price / Book5.15

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees78
Outstanding Shares22,850,000

How to Become a New Pot Stock Millionaire

Mersana Therapeutics (NASDAQ:MRSN) Frequently Asked Questions

What is Mersana Therapeutics' stock symbol?

Mersana Therapeutics trades on the NASDAQ under the ticker symbol "MRSN."

How were Mersana Therapeutics' earnings last quarter?

Mersana Therapeutics Inc. (NASDAQ:MRSN) announced its quarterly earnings data on Wednesday, March, 28th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.13. The business had revenue of $3.26 million for the quarter, compared to the consensus estimate of $4.22 million. View Mersana Therapeutics' Earnings History.

What price target have analysts set for MRSN?

5 equities research analysts have issued 1-year price targets for Mersana Therapeutics' shares. Their forecasts range from $23.00 to $33.00. On average, they expect Mersana Therapeutics' share price to reach $26.00 in the next twelve months. View Analyst Ratings for Mersana Therapeutics.

Who are some of Mersana Therapeutics' key competitors?

Who are Mersana Therapeutics' key executives?

Mersana Therapeutics' management team includes the folowing people:
  • Mr. David M. Mott, Exec. Chairman (Age 53)
  • Ms. Anna Protopapas, Pres, CEO & Director (Age 54)
  • Dr. Timothy B. Lowinger Ph.D., Sr. VP & Chief Scientific Officer (Age 54)
  • Dr. Donald A. Bergstrom, Former Sr. VP & Chief Medical Officer (Age 46)
  • Mr. Mikhail Papisov Ph.D., Co-Founder

When did Mersana Therapeutics IPO?

(MRSN) raised $75 million in an initial public offering (IPO) on Wednesday, June 28th 2017. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Has Mersana Therapeutics been receiving favorable news coverage?

Headlines about MRSN stock have been trending somewhat positive recently, Accern reports. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mersana Therapeutics earned a news impact score of 0.20 on Accern's scale. They also gave news stories about the company an impact score of 44.92 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Mersana Therapeutics?

Shares of MRSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mersana Therapeutics' stock price today?

One share of MRSN stock can currently be purchased for approximately $15.86.

How big of a company is Mersana Therapeutics?

Mersana Therapeutics has a market capitalization of $380.84 million and generates $17.55 million in revenue each year. The company earns $-38,700,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Mersana Therapeutics employs 78 workers across the globe.

How can I contact Mersana Therapeutics?

Mersana Therapeutics' mailing address is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-498-0020 or via email at [email protected]


MarketBeat Community Rating for Mersana Therapeutics (MRSN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  77 (Vote Outperform)
Underperform Votes:  74 (Vote Underperform)
Total Votes:  151
MarketBeat's community ratings are surveys of what our community members think about Mersana Therapeutics and other stocks. Vote "Outperform" if you believe MRSN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRSN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Mersana Therapeutics (NASDAQ:MRSN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Mersana Therapeutics in the last 12 months. Their average twelve-month price target is $26.00, suggesting that the stock has a possible upside of 63.93%. The high price target for MRSN is $33.00 and the low price target for MRSN is $23.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.803.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $26.00$26.00$23.6667$23.6667
Price Target Upside: 63.93% upside48.57% upside68.45% upside68.45% upside

Mersana Therapeutics (NASDAQ:MRSN) Consensus Price Target History

Price Target History for Mersana Therapeutics (NASDAQ:MRSN)

Mersana Therapeutics (NASDAQ:MRSN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/17/2018HC WainwrightSet Price TargetBuy$33.00MediumView Rating Details
4/16/2018CowenReiterated RatingBuyMediumView Rating Details
3/28/2018Leerink SwannReiterated RatingOutperformHighView Rating Details
3/19/2018JPMorgan ChaseDowngradeOverweight -> Neutral$23.00HighView Rating Details
7/24/2017WedbushReiterated RatingOutperform -> Outperform$25.00HighView Rating Details
(Data available from 4/25/2016 forward)

Earnings

Mersana Therapeutics (NASDAQ:MRSN) Earnings History and Estimates Chart

Earnings by Quarter for Mersana Therapeutics (NASDAQ:MRSN)

Mersana Therapeutics (NASDAQ:MRSN) Earnings Estimates

2018 EPS Consensus Estimate: ($8.72)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($2.33)($2.33)($2.33)
Q2 20181($2.26)($2.26)($2.26)
Q3 20181($2.46)($2.46)($2.46)
Q4 20181($1.67)($1.67)($1.67)
Q1 20191$9.82$9.82$9.82

Mersana Therapeutics (NASDAQ MRSN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/28/2018Q4 2017($0.4830)($0.61)$4.22 million$3.26 millionViewListenView Earnings Details
11/9/2017Q3 2017($0.4850)($0.35)$3.93 million$6.27 millionViewN/AView Earnings Details
8/11/2017Q2 2017($0.5570)($6.33)$3.33 million$3.73 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Mersana Therapeutics (NASDAQ:MRSN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Mersana Therapeutics (NASDAQ MRSN) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 75.59%
Insider Trading History for Mersana Therapeutics (NASDAQ:MRSN)
Institutional Ownership by Quarter for Mersana Therapeutics (NASDAQ:MRSN)

Mersana Therapeutics (NASDAQ MRSN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/3/2017M James BarrettMajor ShareholderBuy1,000,000$15.00$15,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Mersana Therapeutics (NASDAQ MRSN) News Headlines

Source:
DateHeadline
-$0.61 EPS Expected for Mersana Therapeutics Inc. (MRSN) This Quarter-$0.61 EPS Expected for Mersana Therapeutics Inc. (MRSN) This Quarter
www.americanbankingnews.com - April 24 at 11:22 PM
Wired News – European Medicines Agency Granted Orphan Drug Designation for Abeona’s ABO-202 Gene Therapy Program in Batten DiseaseWired News – European Medicines Agency Granted Orphan Drug Designation for Abeona’s ABO-202 Gene Therapy Program in Batten Disease
finance.yahoo.com - April 24 at 9:31 AM
Wired News - Krystal Biotechs Lead Product Candidate, KB103, for Treatment of DEB Receives Orphan Medicinal Product Designation in EuropeWired News - Krystal Biotech's Lead Product Candidate, KB103, for Treatment of DEB Receives Orphan Medicinal Product Designation in Europe
finance.yahoo.com - April 23 at 9:14 AM
Mersana Therapeutics (MRSN) Announces New Preclinical Data on Lead ADC Platform Dolaflexin & HER2 Targeted ADC XMT-1522Mersana Therapeutics (MRSN) Announces New Preclinical Data on Lead ADC Platform Dolaflexin & HER2 Targeted ADC XMT-1522
www.streetinsider.com - April 18 at 4:38 PM
Mersana Therapeutics (MRSN) Upgraded to Hold by Zacks Investment ResearchMersana Therapeutics (MRSN) Upgraded to Hold by Zacks Investment Research
www.americanbankingnews.com - April 18 at 9:00 AM
Mersana Therapeutics (MRSN) Given a $33.00 Price Target by HC Wainwright AnalystsMersana Therapeutics (MRSN) Given a $33.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 18 at 8:36 AM
Mersana Therapeutics Inc. (MRSN) Receives Consensus Recommendation of "Hold" from BrokeragesMersana Therapeutics Inc. (MRSN) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 18 at 1:30 AM
Mersana Therapeutics Presents Preclinical Data Further Demonstrating Differentiating Aspects of Its ADC Platform Technology at AACR 2018Mersana Therapeutics Presents Preclinical Data Further Demonstrating Differentiating Aspects of Its ADC Platform Technology at AACR 2018
finance.yahoo.com - April 17 at 4:47 PM
Mersana Therapeutics (MRSN) Coverage Initiated by Analysts at Leerink SwannMersana Therapeutics (MRSN) Coverage Initiated by Analysts at Leerink Swann
www.americanbankingnews.com - April 16 at 10:22 PM
Mersana Therapeutics (MRSN) Research Coverage Started at JPMorgan ChaseMersana Therapeutics (MRSN) Research Coverage Started at JPMorgan Chase
www.americanbankingnews.com - April 16 at 10:22 PM
Cowen Begins Coverage on Mersana Therapeutics (MRSN)Cowen Begins Coverage on Mersana Therapeutics (MRSN)
www.americanbankingnews.com - April 16 at 10:22 PM
Mersana Therapeutics (MRSN) Stock Rating Reaffirmed by CowenMersana Therapeutics (MRSN) Stock Rating Reaffirmed by Cowen
www.americanbankingnews.com - April 16 at 4:16 PM
Mersana Therapeutics (MRSN) Announces Poster Presentations Demonstrating Differentiating Aspects of ADC Platform Technology at AACRMersana Therapeutics (MRSN) Announces Poster Presentations Demonstrating Differentiating Aspects of ADC Platform Technology at AACR
www.streetinsider.com - April 10 at 9:58 AM
Mersana Therapeutics Announces Poster Presentations Demonstrating Differentiating Aspects of ADC Platform Technology at the American Association for Cancer Research Annual Meeting 2018Mersana Therapeutics Announces Poster Presentations Demonstrating Differentiating Aspects of ADC Platform Technology at the American Association for Cancer Research Annual Meeting 2018
finance.yahoo.com - April 9 at 9:48 AM
$3.36 Million in Sales Expected for Mersana Therapeutics Inc. (MRSN) This Quarter$3.36 Million in Sales Expected for Mersana Therapeutics Inc. (MRSN) This Quarter
www.americanbankingnews.com - April 9 at 1:05 AM
Zacks: Analysts Anticipate Mersana Therapeutics Inc. (MRSN) Will Post Earnings of -$0.61 Per ShareZacks: Analysts Anticipate Mersana Therapeutics Inc. (MRSN) Will Post Earnings of -$0.61 Per Share
www.americanbankingnews.com - April 7 at 11:10 PM
Mersana Therapeutics (MRSN) Downgraded by Zacks Investment ResearchMersana Therapeutics (MRSN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 7 at 9:29 AM
Mersana Therapeutics Inc’s (NASDAQ:MRSN) Profit OutlookMersana Therapeutics Inc’s (NASDAQ:MRSN) Profit Outlook
finance.yahoo.com - April 4 at 5:08 PM
Mersana Therapeutics (MRSN) "Outperform" Rating Reaffirmed at Leerink SwannMersana Therapeutics' (MRSN) "Outperform" Rating Reaffirmed at Leerink Swann
www.americanbankingnews.com - April 3 at 7:48 AM
Mersana Therapeutics (MRSN) Announces  Earnings ResultsMersana Therapeutics (MRSN) Announces Earnings Results
www.americanbankingnews.com - March 29 at 7:38 AM
Mersana Therapeutics (MRSN) Rating Increased to Hold at Zacks Investment ResearchMersana Therapeutics (MRSN) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - March 29 at 12:34 AM
Mersana Therapeutics misses by $0.11, misses on revenueMersana Therapeutics misses by $0.11, misses on revenue
seekingalpha.com - March 28 at 9:48 AM
Mersana Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Business UpdatesMersana Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates
finance.yahoo.com - March 28 at 9:48 AM
Does Mersana Therapeutics Inc’s (NASDAQ:MRSN) Past Performance Indicate A Weaker Future?Does Mersana Therapeutics Inc’s (NASDAQ:MRSN) Past Performance Indicate A Weaker Future?
finance.yahoo.com - March 27 at 10:03 AM
$4.22 Million in Sales Expected for Mersana Therapeutics Inc. (MRSN) This Quarter$4.22 Million in Sales Expected for Mersana Therapeutics Inc. (MRSN) This Quarter
www.americanbankingnews.com - March 24 at 9:12 AM
Mersana Therapeutics Inc. (MRSN) Receives Consensus Recommendation of "Hold" from AnalystsMersana Therapeutics Inc. (MRSN) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 24 at 1:44 AM
Mersana Therapeutics (MRSN) Stock Rating Upgraded by Zacks Investment ResearchMersana Therapeutics (MRSN) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 23 at 10:46 PM
Zacks Investment Research Lowers Mersana Therapeutics (MRSN) to HoldZacks Investment Research Lowers Mersana Therapeutics (MRSN) to Hold
www.americanbankingnews.com - March 23 at 7:22 PM
Mersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Full Year 2017 Financial Results and Business UpdatesMersana Therapeutics to Host Conference Call Announcing Fourth Quarter and Full Year 2017 Financial Results and Business Updates
finance.yahoo.com - March 21 at 4:20 PM
Eeny, Meeny, Miny, Moe: JPMorgan Downgrades 4 Biotechs In Portfolio RebalancingEeny, Meeny, Miny, Moe: JPMorgan Downgrades 4 Biotechs In Portfolio Rebalancing
finance.yahoo.com - March 19 at 4:17 PM
Mersana Therapeutics (MRSN) Downgraded by JPMorgan Chase & Co.Mersana Therapeutics (MRSN) Downgraded by JPMorgan Chase & Co.
www.americanbankingnews.com - March 19 at 10:58 AM
Mersana Strengthens Board of Directors Leadership with Appointment of Willard H. Dere, M.D., Professor at the University of Utah and Retired Chief Medical Officer of AmgenMersana Strengthens Board of Directors Leadership with Appointment of Willard H. Dere, M.D., Professor at the University of Utah and Retired Chief Medical Officer of Amgen
finance.yahoo.com - March 19 at 9:44 AM
Mersana Appoints David A. Spellman as Chief Financial OfficerMersana Appoints David A. Spellman as Chief Financial Officer
finance.yahoo.com - March 12 at 10:48 AM
Is a Surprise Coming for Mersana Therapeutics (MRSN) This Earnings Season?Is a Surprise Coming for Mersana Therapeutics (MRSN) This Earnings Season?
finance.yahoo.com - March 7 at 9:41 AM
Mersana Therapeutics Inc (MRSN) Expected to Announce Quarterly Sales of $4.22 MillionMersana Therapeutics Inc (MRSN) Expected to Announce Quarterly Sales of $4.22 Million
www.americanbankingnews.com - March 6 at 4:02 AM
Mersana Therapeutics Inc (MRSN) Short Interest UpdateMersana Therapeutics Inc (MRSN) Short Interest Update
www.americanbankingnews.com - March 3 at 3:26 AM
HC Wainwright Analysts Give Mersana Therapeutics (MRSN) a $33.00 Price TargetHC Wainwright Analysts Give Mersana Therapeutics (MRSN) a $33.00 Price Target
www.americanbankingnews.com - March 2 at 9:24 PM
Mersana Therapeutics Inc (MRSN) Given Average Recommendation of "Buy" by BrokeragesMersana Therapeutics Inc (MRSN) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - February 27 at 1:52 AM
$3.57 Million in Sales Expected for Mersana Therapeutics Inc (MRSN) This Quarter$3.57 Million in Sales Expected for Mersana Therapeutics Inc (MRSN) This Quarter
www.americanbankingnews.com - February 18 at 12:56 PM
HC Wainwright Initiates Coverage on Mersana Therapeutics (MRSN)HC Wainwright Initiates Coverage on Mersana Therapeutics (MRSN)
www.americanbankingnews.com - February 15 at 9:58 AM
Mersana Therapeutics to Present at Upcoming Investor ConferencesMersana Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - February 7 at 9:08 AM
Mersana Therapeutics (MRSN) Rating Increased to Sell at ValuEngineMersana Therapeutics (MRSN) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - February 4 at 9:46 PM
Mersana Therapeutics Inc (MRSN) Given Consensus Rating of "Buy" by AnalystsMersana Therapeutics Inc (MRSN) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - February 2 at 1:48 AM
Zacks: Analysts Set $23.67 Price Target for Mersana Therapeutics Inc (MRSN)Zacks: Analysts Set $23.67 Price Target for Mersana Therapeutics Inc (MRSN)
www.americanbankingnews.com - January 30 at 7:46 AM
Zacks: Analysts Anticipate Mersana Therapeutics Inc (MRSN) Will Post Earnings of -$0.51 Per ShareZacks: Analysts Anticipate Mersana Therapeutics Inc (MRSN) Will Post Earnings of -$0.51 Per Share
www.americanbankingnews.com - January 30 at 5:08 AM
$3.82 Million in Sales Expected for Mersana Therapeutics Inc (MRSN) This Quarter$3.82 Million in Sales Expected for Mersana Therapeutics Inc (MRSN) This Quarter
www.americanbankingnews.com - January 15 at 9:44 PM
 Brokerages Set $23.67 Target Price for Mersana Therapeutics Inc (MRSN) Brokerages Set $23.67 Target Price for Mersana Therapeutics Inc (MRSN)
www.americanbankingnews.com - January 15 at 5:38 PM
-$0.51 Earnings Per Share Expected for Mersana Therapeutics Inc (MRSN) This Quarter-$0.51 Earnings Per Share Expected for Mersana Therapeutics Inc (MRSN) This Quarter
www.americanbankingnews.com - January 13 at 7:52 AM
Mersana Therapeutics Outlines 2017 Milestones and 2018 GoalsMersana Therapeutics Outlines 2017 Milestones and 2018 Goals
finance.yahoo.com - January 8 at 12:04 PM
Zacks Investment Research Downgrades Mersana Therapeutics (MRSN) to SellZacks Investment Research Downgrades Mersana Therapeutics (MRSN) to Sell
www.americanbankingnews.com - January 3 at 11:54 AM

SEC Filings

Mersana Therapeutics (NASDAQ:MRSN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Mersana Therapeutics (NASDAQ:MRSN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Mersana Therapeutics (NASDAQ MRSN) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.